You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 7107 results
  1. Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain

    SBC: 4E THERAPEUTICS, INC.            Topic: 104

    Abstract The goal of this project is to develop an optimized MNK inhibitor for neuropathic pain treatment. MNK is a kinase that phosphorylates eIF4E to control the translation of a distinct subset of mRNAs. Our focus on this target for neuropathic pain is grounded in evidence that MNK-eIF4E signaling is activated in nociceptors upon exposure to pain promoting cytokines and growth factors as well a ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical Vector for TCR Immunotherapy Targeted to Melanoma

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Tolerability of SRX246 in Huntington's Disease Patients

    SBC: Azevan Pharmaceuticals Inc            Topic: 950

    DESCRIPTIONprovided by applicantHuntington s DiseaseHDis an inherited disease that results from expansion of a trinucleotideCAGcytosine adenine guaninerepeat that encodes a polyglutamine tract in the huntingtin proteinPsychiatric symptomsincluding irritability and aggressionare common in HD patientsThese are among the most distressing aspects of the diseaseThey have adverse effects on daily life a ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. CATHEPSIN L INHIBITORS AS PAN CORONAVIRUS THERAPEUTICS

    SBC: PHELIX THERAPEUTICS LLC            Topic: R

    DESCRIPTION provided by applicant Coronaviruses CoV are RNA viruses that cause gastrointestinal respiratory and neurological symptoms in several mammalian species The outbreak of the severe acute respiratory syndrome CoV SARS CoV in humans was fatal in of infected patients infecting people and killing The recent incidents involving the highly pathogenic Middle East ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Virtual Bone Biopsy: Transfer to the clinical arena

    SBC: MICROMRI, INC.            Topic: N/A

    Osteoporosis is a major community health problem for which several effective FDA approved therapies exist, but which remains largely undiagnosed and untreated. While bone densitometry using dual-energy x-ray absorptiometry (DXA) is the current "gold standard" in osteoporosis diagnosis, controlled clinical trials have highlighted its sensitivity and specificity limitations at the individual patient ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma

    SBC: Linnaeus Therapeutics LLC            Topic: 102

    Project Summary:Although recent advances in immune and targeted therapies have dramatically improved outcomes for many patients with advanced cancer, durable responses are achieved in only a minority of patients, and treatment is frequently limited by significant side effects. There is an urgent need to identify new therapeutic targets and efficacious pharmacologic agents that selectively engage t ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. A novel diagnostic Kit for Hepatocellular Carcinoma

    SBC: ImCare Biotech LLC            Topic: 102

    PROJECT SUMMARY ImCare Biotech is seeking to commercialize Seravue®, an ELISA-based diagnostic system that is able to identify both early and late stage Hepatocellular Carcinoma (HCC) with high sensitivity and specificity. With NCI- supported Phase I and II SBIR awards plus internal and external investor support, ImCare completed the technical development of the Seravue® product and now requests ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. VGo-Assist, A Mobile Telepresence Robot to Engage Persons with Alzheimer's Disease and Related Dementias

    SBC: VECNA TECHNOLOGIES, INC            Topic: NIA

    Project Summary/Abstract Assistive Technologies (AT) is a broad area of activities to support physical health, well-being, social connectedness, and ability to live independently at home. Assistive Robotics (AR) has largely referred to robots that assisted people through physical interaction, while Socially Interactive Robotics (SIR) describe machines that interact primarily through social interac ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    SBC: SAVARA INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIA

    Muscle-aging is defined by progressive declines in mass and strength that poses a high risk for falls, fatal injury, and trauma-related fractures among older Americans (age 60+). Each year, rt30% of older adults suffer a fall, resulting in ~2.8 million traumatic fractures that significantly reduce mobility, independence, overall health, and quality of life for the elderly. Among fall-related injur ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government